

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer; HCV	Unknown	<p>A two-step synthesis procedure produced arylethynyltriazole ribonucleosides that may be useful for treating cancer and HCV infection. In HCV replicon assays, two of the nucleoside analogs showed antiviral activity with minimal adverse effects against host cells. In xenograft mice with drug-resistant human pancreatic cancer cells, intraperitoneal injection of a third nucleoside analog every three days for four weeks significantly decreased tumor growth and proliferation compared with that seen in untreated controls ($p < 0.05$). Next steps include evaluating the toxicity, pharmacokinetics and pharmacodynamics of the arylethynyltriazole ribonucleosides.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.265 Published online Feb. 19, 2009</p>	<p>Patent applications filed covering the arylethynyltriazole ribonucleosides; anti-HCV application available for licensing from the Catholic University Leuven Contact: Sandra Vanvlasselaer, Catholic University Leuven, Leuven, Belgium e-mail: Sandra.Vanvlasselaer@lrd.kuleuven.be</p> <p>Anticancer application available for licensing from INSERM Transfert Contact: Nicolas Crouvezier, INSERM Transfert, Paris, France e-mail: nicolas.crouvezier@inserm-transfert.fr</p>	<p>Wan, J. <i>et al. J. Med. Chem.</i>; published online Jan. 26, 2009; doi:10.1021/jm800927r Contact: Ling Peng, University of the Mediterranean Aix-Marseille II, Marseille, France e-mail: ling.peng@univmed.fr</p>